Stock 2197 CLOVER BIOPHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Clover Biopharmaceuticals, Ltd.

Equities

2197

KYG2280A1076

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:22 29/04/2024 BST 		5-day change 1st Jan Change
0.345 HKD -4.17% Intraday chart for Clover Biopharmaceuticals, Ltd. +6.15% -44.35%
04-12 Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding CI
04-08 Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 In Initial Young Adult Cohort
Clover Biopharmaceuticals Trims Losses in 2023
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
Clover Biopharmaceuticals Swings to Profit in H1
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Slowdown in China's Industry, Retail Keep Hong Kong Stocks in Slump; Clover Biopharmaceuticals Drops 7%
Clover Biopharmaceuticals Expects Swing to Profit in H1
Clover Biopharmaceuticals, Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Six Months Ended June 30, 2023
Clover Biopharmaceuticals, Ltd. Provides Updates on Business and R&D Pipeline Development
Clover Biopharmaceuticals, Ltd. Establishes Commercial Partnership with Keyuan Xinhai Medical Products Trading Co. Ltd
Clover Biopharmaceuticals, Ltd. Announces Change of Joint Company Secretary
Clover Biopharmaceuticals' 2022 Loss Narrows; Shares Tumble 9%
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Clover Biopharmaceuticals, Ltd. Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China
Clover Launches Covid-19 Booster Vaccine in the People’s Republic of China
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2197 Stock
  4. News Clover Biopharmaceuticals, Ltd.
  5. Other languages